Provided by Tiger Trade Technology Pte. Ltd.

INNOCARE

12.840
+1.0008.45%
Volume:25.60M
Turnover:328.30M
Market Cap:22.62B
PE:-47.56
High:13.300
Open:11.900
Low:11.700
Close:11.840
52wk High:20.620
52wk Low:5.650
Shares:1.76B
HK Float Shares:1.49B
Volume Ratio:1.98
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.270
ROE:-3.55%
ROA:-2.10%
PB:3.01
PE(LYR):-47.56
PS:14.07

Loading ...

Innocare Shares Surge Over 11% on First-Ever Profitability Milestone

Stock News
·
Yesterday

INNOCARE Shares Surge Over 4% in Morning Session as Company Posts First-Ever Profit, Core Drug Orelabrutinib Drives Significant Growth

Stock News
·
Feb 05

InnoCare Pharma (09969) Announces Monthly Return for January 2026

Bulletin Express
·
Feb 04

A Look At InnoCare Pharma (SEHK:9969) Valuation As It Targets First Profit On 2025 Revenue Growth

Simply Wall St.
·
Feb 02

Zhitong Hong Kong Stock Morning Briefing | State Council Issues Plan to Accelerate New Growth Points in Service Consumption, Gold and Silver Plunge Overnight

Stock News
·
Jan 30

InnoCare Pharma Expects Turnaround to Profit in 2025

MT Newswires Live
·
Jan 29

Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now

Simply Wall St.
·
Jan 26

An Intrinsic Calculation For InnoCare Pharma Limited (HKG:9969) Suggests It's 45% Undervalued

Simply Wall St.
·
Jan 06

INNOCARE (09969) Grants 1.4 Million Restricted Share Units

Stock News
·
Dec 31, 2025

Guoyuan International Sets INNOCARE (09969) Target Price at HK$16.81 with "Buy" Rating

Stock News
·
Dec 24, 2025

Is InnoCare Pharma (SEHK:9969) Quietly Recasting Its Future Around Autoimmune Dermatology?

Simply Wall St.
·
Dec 21, 2025

HK Stock Movement | INNOCARE (09969) Rises Over 4% as Self-Developed Novel TYK2 Inhibitor ICP-332 Gains Approval for Phase II/III Clinical Trials in CSU Treatment

Stock News
·
Dec 19, 2025

InnoCare Pharma Receives Regulatory Approval to Begin Clinical Trial of Drug in Systemic Lupus

MT Newswires Live
·
Dec 15, 2025

InnoCare Pharma (SEHK:9969): Assessing Valuation After Landmark NTRK Solid-Tumor Approval for Zurletrectinib

Simply Wall St.
·
Dec 15, 2025

Innocare Pharma Limited (688428.SH): Orelabrutinib Meets Primary Endpoint in Phase IIb Study for Systemic Lupus Erythematosus

Stock News
·
Dec 14, 2025

First Solid-Tumor Drug Approval Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)

Simply Wall St.
·
Dec 13, 2025

HK Stock Movement | INNOCARE (09969) Rises Over 3% as NDA Submission for Zorletinib in Pediatric Patients Expected Soon

Stock News
·
Dec 12, 2025

Everest Medicines (01952) Announces Strategic Collaboration with Haisco; Silver Prices Hit Record High

Stock News
·
Dec 12, 2025

InnoCare Pharma Gets China Nod for Tumor Drug

MT Newswires Live
·
Dec 11, 2025

InnoCare Pharma (09969) Releases Monthly Return for 30 November 2025, No Changes in Share Capital

Bulletin Express
·
Dec 04, 2025